Enlivex operates through two parallel strategies: developing Allocetra™, a macrophage-based cell therapy targeting age-related knee osteoarthritis, and managing a digital asset treasury anchored in the RAIN prediction markets protocol on Arbitrum. Allocetra™ uses apoptotic cell signaling to restore macrophage homeostasis in joint tissue. Its Nasdaq listing provides investors with exposure to both longevity therapeutics development and decentralized prediction markets infrastructure.
